La Jolla Pharmaceutical (NASDAQ: LJPC) was downgraded by Zacks Investment Research from a “buy” rating to a “keep” rating in a research note released Tuesday, Zacks.com reports.
According to Zacks, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.
NASDAQ: LJPC opened at $ 4.37 on Tuesday. The company’s 50-day mobile average price is $ 4.10, and its two-hundred-day mobile average price is $ 4.15. La Jolla Pharmaceutical has a twelve month low of $ 3.35 and a twelve month high of $ 7.85. The stock has a market cap of $ 120.28 million, a P / E ratio of 13.66 and a beta of 2.26.
La Jolla Pharmaceutical (NASDAQ: LJPC) last reported its quarterly results on Thursday, November 4. The biopharmaceutical company announced ($ 0.08) EPS for the quarter, missing the consensus estimate of ($ 0.07) from ($ 0.01). La Jolla Pharmaceutical had a net margin of 16.67% and a negative return on equity of 15.92%. The company posted revenue of $ 13.31 million for the quarter, compared to a consensus estimate of $ 12.10 million. As a group, equity analysts expect La Jolla Pharmaceutical to post earnings per share of 0.53 for the current year.
Meanwhile, director David A. Ramsay bought 10,000 shares of the company in a trade on Monday, December 6. The stock was purchased at an average price of $ 3.82 per share, for a total value of $ 38,200.00. The transaction was disclosed in a legal file with the Securities & Exchange Commission, accessible through the SEC website. In addition, director Kevin C. Tang sold 193,403 shares of the company in a transaction dated Monday, November 29. The shares were sold for an average price of $ 4.10, for a total value of $ 792,952.30. Disclosure of this sale can be found here. Company insiders own 36.30% of the company’s shares.
Large investors have recently bought and sold stocks. Connor Clark & Lunn Investment Management Ltd. purchased a new equity stake in La Jolla Pharmaceutical in the third quarter valued at approximately $ 40,000. LMR Partners LLP purchased a new position in shares of La Jolla Pharmaceutical during the second quarter valued at approximately $ 49,000. Marshall Wace LLP purchased a new position in shares of La Jolla Pharmaceutical during the second quarter valued at approximately $ 67,000. Cubist Systematic Strategies LLC purchased a new position in shares of La Jolla Pharmaceutical during the first quarter valued at approximately $ 69,000. Finally, HighVista Strategies LLC purchased a new position in shares of La Jolla Pharmaceutical during the third quarter valued at approximately $ 102,000.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Co operates as a biopharmaceutical company. He is committed to the discovery, development and commercialization of therapies designed to improve outcomes in patients with life-threatening illnesses. Its product portfolio includes GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, California.
Read more: What is a candlestick chart?
Get a Free Copy of Zacks’ La Jolla Pharmaceutical (LJPC) Research Report
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in La Jolla Pharmaceutical right now?
Before you consider La Jolla Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and La Jolla Pharmaceutical was not on the list.
While La Jolla Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here